A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy
Lumbosacral radiculopathy is one of the leading of cause of disability in the U.S. and worldwide. Among recent reviews evaluating epidural steroid injections, some 1 but not all 2 concluded them to be effective in the long-term. In our own double-blind, placebo-controlled study evaluating epidural etanercept, the results showed significant benefit in favor of the etanercept group, but no subject was included with a duration of pain > 9 months, and the results of this study have yet to be replicated.
Currently, epidural steroid injections are the most frequently performed procedures in pain clinics across the U.S. However, epidural steroids may benefit only a select group of patients. The literature on treating sciatica is notable for a lack of randomized comparative studies involving various treatments. The objective of this project is to conduct a 3-arm study to determine the efficacy of 1) transforaminal epidural corticosteroids; and 2) transforaminal epidural etanercept, in patients with lumbosacral radiculopathy.
|Lumbosacral Radiculopathy||Drug: etanercept Drug: methylprednisolone Drug: normal saline||Phase 2 Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
- Numerical Rating Leg Pain Score [ Time Frame: 1 month ]0-10 pain score. 0= no pain, 10= worst imaginable pain.
- Oswestry Disability Score [ Time Frame: 1 month ]0-100%. 0= no disability, 100% is complete disability
- Global Perceived Effect [ Time Frame: 1 month ]Satisfaction. Number of participants with positive perceived global satisfaction.
- Medication Reduction [ Time Frame: 1 month ]Number of people who reduced medications
|Study Start Date:||August 2008|
|Study Completion Date:||March 2011|
|Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
Epidural etanercept 4 mg, two doses 2 weeks apart
Two transforaminal epidural injections of 4 mg, two weeks apart
Active Comparator: 2
Epidural methylprednisolone 60 mg, two doses 2 weeks apart
Two transforaminal epidural steroid injections with 60 mg, two weeks apart
Placebo Comparator: 3
Epidural saline, two doses 2 weeks apart
Drug: normal saline
Two transforaminal epidural saline injections, two weeks apart
This is a 3-arm multi-center, randomized, double-blind, placebo-controlled study comparing two treatments with transforaminal epidural saline. Each group will receive a 2nd procedure identical to the first 2 weeks after the initial procedure.
Seventy-eight study participants will be randomized via a computerized randomization system using SPSS software in groups of 6 at each institution by a research nurse not involved in patient care. There will be 26 patients in each of the 3 groups. A physician unaware of the patient's treatment group will place 22-gauge needles in the relevant foramen under fluoroscopic guidance as determined by patient's symptoms and MRI findings. Once correct placement is confirmed by contrast injection, the blinded physician will leave the room and another physician will inject the medication. In group I, this will be 60 mg of depo-methylprednisolone. In group II, this will be 4 mg of etanercept reconstituted in 2 ml of sterile water. In group III, this will be normal saline.
Two weeks after the initial procedure, an identical procedure to the first one will be done by the same physician or his designate. In addition to the study medication, each patient in each group will receive 0.5 ml of 0.5% bupivacaine local anesthetic for immediate pain relief during both injections before the study drug is delivered. The efficacy of blinding will be assessed by a disinterested observer unaware of the randomization results after the second procedure before discharge. Follow-up visits will be conducted one, three and six months after the second injection, for those subjects who continue to experience > 50% pain relief.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00733096
|United States, District of Columbia|
|Walter Reed Army Medical Center|
|Washington, District of Columbia, United States, 20307|
|United States, North Carolina|
|Womack Army Medical Center|
|Fort Bragg, North Carolina, United States|